Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Elzach – page 22

608 clinical trials in Elzach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Elzach at a glance
608
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

608 trials in Elzach

Open in trial search

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diabetic retinal oedema

Not yet recruiting

Efficacy and safety of intravitreal MK-8748 versus aflibercept in adults with diabetic macular edema

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Angina pectoris

Not yet recruiting

Study of Sublingual Glyceryl Trinitrate Spray to Reduce Angina in Adults with Symptomatic Coronary Artery Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glyceryl Trinitrate
  • Sponsor:G. Pohl-Boskamp GmbH & Co. KG

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Non-small cell lung cancer

Not yet recruiting

Safety and efficacy of rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Elzach

What the registry says about research in the country

01 Neurological Pain Management

Clinical research focusing on chronic pain management in patients affected by various forms of neuropathy, including both peripheral and central nervous system conditions.

  • Traumatic Neuropathy
  • Post-operative Peripheral Neuropathy
  • Central Neuropathy

These trials evaluate the effectiveness of AP707 as an add-on treatment, aiming to improve pain management outcomes for patients with chronic neuropathic conditions.

02 Pain Therapeutics

Investigating novel approaches to treating chronic neuropathic pain through targeted therapeutic interventions, with a focus on both traumatic and disease-related nerve damage.

  • Pain Management Protocols
  • Treatment Tolerability
  • Therapeutic Efficacy

Research aims to enhance treatment options for patients suffering from various types of neuropathic conditions, exploring new therapeutic combinations.

03 Neuropathy Research

Comprehensive studies examining the impact of innovative treatments on peripheral and central nervous system disorders, particularly focusing on pain management strategies.

  • Post-surgical Complications
  • Trauma-induced Neuropathy
  • Central Nervous System Conditions

The research evaluates new therapeutic approaches for managing chronic neuropathic pain across different patient populations and conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.